-+ 0.00%
-+ 0.00%
-+ 0.00%

Fate Therapeutics shareholders approve 7 million-share increase to equity incentive plan

PUBT·06/15/2026 20:04:08
Listen to the news
Fate Therapeutics shareholders approve 7 million-share increase to equity incentive plan
  • Fate Therapeutics held its annual shareholder meeting on June 12, 2026.
  • Shareholders adopted a third amended and restated 2022 Stock Option and Incentive Plan, adding 7 million shares to the pool.
  • Ernst & Young was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-271055), on June 15, 2026, and is solely responsible for the information contained therein.